Founded in 2000, the Company's initial technology platforms were developed at the Massachusetts General Hospital and Harvard Medical School under the direction of Dr. Ralph Weissleder, Professor of Radiology and Director of the Center for Molecular Imaging Research at the MGHl.

The Company's FMT System and Optical Probe Portfolio harness the well-known power of fluorescent technology in vivo by providing quantifiable molecular reporting in a range of diseases from deep within the body. These powerful sets of technologies open the door to VisEn's two breakthrough market opportunities: imaging of disease progression and pharmaceutical activity in animals for general research and pharmaceutical drug development, and clinical molecular imaging of disease processes in humans. With these groundbreaking products, a deep understanding of the chemistries and biologies of agents and disease, and through applications developed with leading research and pharmaceutical partners, VisEn is giving meaning and metrics to molecular imaging today.